TNON TNON
Company Profile ↓Company Overview
TNON (TNON) is a publicly traded company listed on with a market capitalization of $2.06M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 78.7% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $3.94M (+20.4% YoY); net profit $-12.56M.
- Trailing 12 Months Year-on-year growth — revenue +20.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 78.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 78.71% |
| 1 Year: | 20.35% |
Stock Price Performance
| 1 Year: | -86.86% |
| 6 Months: | -74.70% |
| 3 Months: | -74.12% |
| 1 Month: | -22.35% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)31.92 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 78.7% over 5 years.
CONS
- Trading 88.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.00K | 22.00K | 70.00K | 71.00K | 135.00K | 208.00K | 433.00K | 743.00K | 944.00K | 719.00K | 901.00K | 887.00K | - | 726.00K | 564.00K | 1.17M | 1.48M | 1.38M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 403.00K | 319.00K | 400.00K | 464.00K | 434.00K |
| Gross Profit | 4.00K | 13.00K | 52.00K | -204.00K | -136.00K | -94.00K | -47.00K | 194.00K | 535.00K | 470.00K | 470.00K | 418.00K | - | 323.00K | 245.00K | 773.00K | 1.02M | 945.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.00M | 3.10M | 4.17M | 3.88M | 4.22M |
| Operating Income | -189.00K | -1.61M | -2.10M | -2.08M | -5.46M | -3.26M | -4.89M | -4.32M | -3.38M | -3.51M | -3.87M | -3.21M | - | -3.68M | -2.86M | -3.39M | -2.87M | -3.28M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.51M | -2.65M | -3.19M | -2.67M | -3.15M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 176.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.62M | -2.77M | -3.34M | -2.83M | -3.48M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -200.00K | -1.67M | -2.34M | -2.35M | -5.49M | -3.17M | -4.83M | -4.29M | -3.33M | -3.58M | -3.83M | -3.18M | - | -3.62M | -2.77M | -3.34M | -2.83M | -3.48M |
| Diluted EPS | - | -2.01 | -2.55 | -2.38 | -0.65 | -2.82 | -4.30 | -3.28 | -11.69 | -10.02 | -8.16 | -3.63 | - | -1.01 | -0.36 | -0.40 | - | -0.31 |
| R&D Expense | 87.00K | 237.00K | 601.00K | 562.00K | 657.00K | 797.00K | 834.00K | 901.00K | 737.00K | 669.00K | 708.00K | 657.00K | - | 691.00K | 503.00K | 428.00K | - | 662.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 691.00K | 2.93M | 3.28M | 3.94M |
| Cost of Revenue | - | 1.33M | 1.69M | 1.57M | 1.59M |
| Gross Profit | - | -641.00K | 1.24M | 1.71M | 2.36M |
| Operating Expenses | - | 18.08M | 16.97M | 15.48M | 15.15M |
| Operating Income | - | -18.73M | -15.73M | -13.77M | -12.79M |
| EBITDA | - | -18.27M | -15.13M | -12.98M | -12.03M |
| Interest Expense | - | 354.00K | 21.00K | 34.00K | 0 |
| Pretax Income | - | -18.92M | -15.58M | -13.67M | -12.56M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -18.92M | -15.58M | -13.67M | -12.56M |
| Diluted EPS | - | -188.96 | -68.72 | -11.26 | -1.70 |
| R&D Expense | 1.72M | 2.83M | 3.16M | 2.60M | 2.15M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | - | 11.09M | 6.34M | 9.84M | 10.76M |
| Current Assets | - | - | 9.35M | 3.89M | 8.21M | 6.77M |
| Cash & Equivalents | - | - | 2.13M | 2.43M | 6.54M | 3.76M |
| Inventory | - | - | 415.00K | 554.00K | 606.00K | 1.05M |
| Receivables | - | - | 228.00K | 518.00K | 863.00K | 1.70M |
| Total Liabilities | - | - | 4.84M | 5.57M | 3.87M | 5.72M |
| Current Liabilities | - | - | 2.53M | 3.14M | 1.87M | 3.21M |
| Long Term Debt | - | - | - | - | - | - |
| Total Debt | - | - | 911.00K | 1.86M | 428.00K | 141.00K |
| Total Equity | -2.71M | - | 6.25M | 778.00K | 5.97M | 5.04M |
| Shares Outstanding | - | - | 140.46K | 325.04K | 3.14M | 10.85M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -12.03M | -12.18M | -9.88M | -10.74M |
| Investing Cash Flow | - | -2.88M | 6.14M | -186.00K | -1.02M |
| Financing Cash Flow | - | 14.11M | 6.30M | 14.12M | 8.99M |
| Capital Expenditure | - | -847.00K | -361.00K | -186.00K | -273.00K |
| Free Cash Flow | - | -12.87M | -12.54M | -10.06M | -11.02M |
| Net Change in Cash | - | -795.00K | 261.00K | 4.06M | -2.78M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | -92.8% | 42.4% | 52.2% | 59.8% |
| Operating Margin % | - | -2,709.8% | -537.1% | -420.1% | -324.3% |
| Net Margin % | - | -2,737.6% | -532.1% | -417.2% | -318.4% |
| ROE % | - | -302.6% | -2,002.7% | -229.0% | -249.1% |
| ROCE % | - | -218.8% | -490.7% | -172.6% | -169.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TNON
Tenon Medical, Inc. Sets Date for Second Quarter 2026 Earnings
LOS GATOS, CA / ACCESS Newswire / July 30, 2026 / Tenon Medical, Inc.(NASDAQ:TNON)("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, today announced plans to…
Tenon Medical, Inc. Announces Regained Compliance with Nasdaq Stockholders' Equity Requirement
LOS GATOS, CA / ACCESS Newswire / July 20, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, today announced that i…
Tenon Medical(R) Announces FDA 510(k) Clearance for Catamaran(R) SI Joint Fusion System
~ Updated clearance incorporates various instrument upgrades, as well as per-procedure costs, improving unit economics driven by the reclassification of certain instruments from disposable to reusable status ~ ~ Clearance reflects Tenon's c…
WallachBeth Capital Announces Closing of Tenon Medical, Inc. $4.2 Million Public Offering
WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that Tenon Medical, Inc. (NASDAQ: TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care…
Tenon Medical, Inc. Announces Closing of $4.2 Million Public Offering
LOS GATOS, CA / ACCESS Newswire / July 1, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, announced that it has c…
WallachBeth Capital Announces Pricing of Tenon Medical, Inc. $4.2 Million Public Offering
WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care …
TNON — Frequently Asked Questions
What is the current share price of TNON?
As of 2026-08-05 17:25 PDT, TNON trades at $0.19 on NASDAQ/NYSE. Its 52-week range is $0.18 to $1.67.
What is the market capitalisation of TNON?
TNON has a market capitalisation of $2.06M on NASDAQ/NYSE.
What is the P/E ratio of TNON?
TNON trades at a trailing price-to-earnings (P/E) ratio of -0.11. Its price-to-book (P/B) ratio is 0.41.
Is TNON a good stock to buy?
This page provides a data-driven analysis of TNON, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.